JPMorgan Chase & Co. Grows Position in Haleon plc (NYSE:HLN)

JPMorgan Chase & Co. increased its position in Haleon plc (NYSE:HLN) by 25.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,084,202 shares of the company’s stock after purchasing an additional 1,026,939 shares during the period. JPMorgan Chase & Co. owned 0.11% of Haleon worth $53,791,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in HLN. Fortitude Family Office LLC purchased a new stake in shares of Haleon in the 3rd quarter worth about $28,000. Toronto Dominion Bank increased its stake in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares in the last quarter. Prospera Private Wealth LLC purchased a new position in shares of Haleon during the third quarter valued at approximately $57,000. BOKF NA boosted its position in shares of Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its position in shares of Haleon by 21.4% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 7,569 shares of the company’s stock worth $63,000 after purchasing an additional 1,334 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on HLN shares. UBS Group upgraded Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon presently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Price Performance

NYSE HLN opened at $9.46 on Friday. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The stock has a 50-day moving average of $9.64 and a 200 day moving average of $9.65. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company has a market capitalization of $42.82 billion, a price-to-earnings ratio of 27.82, a PEG ratio of 2.95 and a beta of 0.28.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.